Prosaposin deficiency (pSap-d) and saposin B deficiency (SapB-d) are both lipid storage disorders caused by mutations in the PSAP gene that codes for the 65-70 kDa prosaposin protein, which is the precursor for four sphingolipid activator proteins, saposins A-D. We report on two new patients with PSAP gene defects; one, with pSap-d, who had a severe neurovisceral dystrophy and died as a neonate, and the other with SapB-d, who presented with a metachromatic leukodystrophy-like disorder but had normal arylsulfatase activity. Screening for urinary sphingolipids was crucial to the diagnosis of both patients, with electrospray ionization tandem mass spectrometry also providing quantification. The pSap-d patient is the first case with this condition where urinary sphingolipids have been investigated. Multiple sphingolipids were elevated, with globotriaosylceramide showing the greatest increase. Both patients had novel mutations in the PSAP gene. The pSap-d patient was homozygous for a splice-acceptor site mutation two bases upstream of exon 10. This mutation led to a premature stop codon and yielded low levels of transcript. The SapB-d patient was a compound heterozygote with a splice-acceptor site variant exclusively affecting the SapB domain on one allele, and a 2 bp deletion leading to a null, that is, pSap-d mutation, on the other allele. Phenotypically, pSap-d is a relatively uniform disease of the neonate, whereas SapB-d is heterogeneous with a spectrum similar to that in metachromatic leukodystrophy. The possible existence of genotypes and phenotypes intermediate between those of pSap-d and the single saposin deficiencies is speculated.

Charles University Prague 1st Medical Faculty Institute of Inherited Metabolic Disorders of 1st Faculty of Medicine and General Teaching Hospital Prague Czech Republic

Zobrazit více v PubMed

Asfaw B, Schindler D, Ledvinová J, Černý B, Šmíd F, Conzelmann E. Degradation of blood group A glycolipid A-6-2 by normal and mutant human skin fibroblasts. J Lipid Res. 1998;39:1768–1780. PubMed

Berná L, Asfaw B, Conzelmann E, Černý B, Ledvinová J. Determination of urinary sulfatides and other lipids by combination of reversed-phase and thin-layer chromatographies. Anal Biochem. 1999;26:304–311. PubMed

Bradová V, Šmíd F, Ulrich-Bott B, Roggendorf W, Paton BC, Harzer K. Prosaposin deficiency: Further characterization of the sphingolipid activator protein-deficient sibs. Hum Genet. 1993;92:143–152. PubMed

De Hoffmann E, Stroobant V. External standard method. Sources of error. Internal standard method. In: De Hoffmann E, Stroobant V, editors. Mass spectrometry: Principles and applications. 2nd edition. Chichester, New York: John Wiley & Sons; 2002. pp. 199–203.

Deconinck N, Messaaoui A, Ziereisen F, Kadhim H, Sznajer Y, Pelc K, Nassogne MC, Vanier M-T, Dan B. Metachromatic leukodystrophy without arylsulfatase A deficiency: A new case of saposin-B deficiency. Eur J Paediatr Neurol. 2008;12:46–50. [epub July 2007] PubMed

Desnick RJ, Sweeley CC, Krivit W. A method for the quantitative determination of neutral glycosphingolipids in urine sediment. J Lipid Res. 1970;11:31–37. PubMed

Diaz-Font A, Cormand B, Santamaria R, Vilageliu L, Grinberg D, Chabás A. A mutation within the saposin D domain in a Gaucher disease patient with normal glucocerebosidase activity. Hum Genet. 2005;117:275–277. PubMed

Elleder M, Jeřábková M, Befekadu A, Hřebíček M, Berná L, Ledvinová J, Hůlková H, Rosewich H, Schymik N, Paton BC, Harzer K. Prosaposin deficiency—A rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. Neuropediatrics. 2005;36:171–180. PubMed

Fujita N, Suzuki K, Vanier M-T, Popko B, Maeda N, Klein A, Henseler M, Sandhoff K, Nakayasu H, Suzuki K. Targeted disruption of the mouse sphingolipid activator protein gene: A complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet. 1996;5:711–725. PubMed

Fuller M, Sharp PC, Rozaklis T, Whitfield PD, Blacklock D, Hopwood JJ, Meikle PJ. Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin Chem. 2005;51:688–694. PubMed

Hahn AF, Gordon BA, Feleki V, Hinton GG, Gilbert JJ. A variant form of metachromatic leukodystrophy without arylsulfatase deficiency. Ann Neurol. 1982;12:33–36. PubMed

Han X, Gross RW. Shotgun lipidomics: Electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev. 2005;24:367–412. PubMed

Harzer K, Paton BC, Poulos A, Kustermann-Kuhn B, Roggendorf W, Grisar T, Popp M. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: Biochemical signs of combined sphingolipidoses. Eur J Pediatr. 1989;149:31–39. PubMed

Henseler M, Klein A, Reber M, Vanier M-T, Landrieu P, Sandhoff K. Analysis of splice-site mutation in the sap-precursor gene of a patient with metachromatic leukodystrophy. Am J Hum Genet. 1996;58:65–74. PubMed PMC

Holtschmidt H, Sandhoff K, Kwon HY, Harzer K, Nakano T, Suzuki K. Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J Biol Chem. 1991;266:7556–7560. PubMed

Hůlková H, Červenková M, Ledvinová J, Tocháčková M, Hřebíček M, Poupetová H, Befekadu A, Berná L, Paton BC, Harzer K, Böör A, Šmíd F, Elleder M. A novel mutation in the coding region of the prosaposin gene leads to complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. Hum Mol Genet. 2001;10:927–940. PubMed

Li S-C, Kihara H, Serizawa S, Li Y-T, Fluharty AL, Mayes JS, Shapiro LJ. Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. Deficiency in urine of patients affected with cerebroside sulfatase activator deficiency and identity with activators for the enzymatic hydrolysis of GM1 ganglioside and globotriaosylceramide. J Biol Chem. 1985;260:1867–1871. PubMed

Liebisch G, Drobnik W, Reil M, Trumbach B, Arnecke R, Olgemoller B, Roscher R, Schmitz G. Quantitative measurement of different ceramide species from crude cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS/MS) J Lipid Res. 1999;40:1539–1546. PubMed

Matsuda J, Kido M, Tadano-Aritomi K, Ishizuka I, Tominaga K, Toida K, Takeda E, Suzuki K, Kuoda Y. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in the mouse. Hum Mol Genet. 2004;13:2709–2723. PubMed

Millat G, Verot L, Rodriguez-Lafrasse C, DiMarco JN, Rimet Y, Poujol A, Girard N, Monges G, Livet MO, Vanier M-T. Fourth reported family with prosaposin deficiency. In: Elleder M, Ledvinová J, Hřebíček M, Poupetová H, Kožich V, editors. Book of abstracts 14th ESGLD workshop (september 18th–21st, 2003) Podebrady/Prague: Guarant Ltd; 2003. p. 81.

Mills K, Johnson A, Winchester B. Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett. 2002;515:171–176. PubMed

Rafi MA, Amini S, Zhang X-L, Wenger DA. Correction of sulfatide metabolism after transfer of prosaposin cDNA to cultured cells from a patient with SAP-1 deficiency. Am J Hum Genet. 1992;50:1252–1258. PubMed PMC

Sandhoff K, Kolter T, Harzer K. Sphingolipid activator proteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and molecular bases of inherited diseases. 8th edition. New York: McGraw-Hill; 2001. pp. 3371–3388.

Schlote W, Harzer K, Christomanou H, Paton BC, Kustermann-Kuhn B, Schmid B, Seeger J, Beudt U, Schuster I, Langenbeck U. Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical, and immunological study. Eur J Pediatr. 1991;150:584–591. PubMed

Schnabel D, Schröder M, Fürst W, Klein A, Hurwitz R, Zenk T, Weber J, Harzer K, Paton BC, Poulos A, Suzuki K, Sandhoff K. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem. 1992;267:3312–3315. PubMed

Spiegel R, Bach G, Sury V, Mengistu G, Meidan B, Shalev S, Shneor Y, Mandel H, Zeigler M. A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: First report of saposin A deficiency in humans. Mol Genet Metab. 2005;84:160–166. PubMed

Sun Y, Witte DP, Zamzow M, Ran H, Quinn B, Matsuda J, Grabowski GA. Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and α−hydroxy ceramide accumulation, and altered prosaposin trafficking. Hum Mol Genet. 2007;16:957–971. PubMed

Tylki-Szymańska A, Czartoryska B, Vanier M-T, Poorthuis BJMH, Groener JAE, Ługowska A, Millat G, Vaccaro AM, Jurkiewicz E. Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet. 2007;72:538–542. [epub October 2007] PubMed

Wenger DA, DeGala G, Williams C, Taylor HA, Stevenson RE, Pruitt JR, Miller J, Garen PD, Balentine JD. Clinical, pathological, and biochemical studies on an infantile case of sulfatide/GM1 activator protein deficiency. Am J Med Genet. 1989;33:255–265. PubMed

Whitfield PD, Sharp PC, Johnson DW, Nelson P, Meikle PJ. Characterization of urinary sulfatides in metachromatic leukodystrophy using electrospray ionization-tandem mass spectrometry. Mol Genet Metab. 2001;73:30–37. PubMed

Hematopoietic stem cell transplantation leads to biochemical and functional correction in two mouse models of acid ceramidase deficiency

Skin inflammation and impaired adipogenesis in a mouse model of acid ceramidase deficiency

N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV

Direct tandem mass spectrometric profiling of sulfatides in dry urinary samples for screening of metachromatic leukodystrophy

The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations